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STROMAL ACTIVATION IN BREAST CANCER 
CARL A. CERAOLO 
ABSTRACT 
 Epithelial-derived cancers such as breast cancer consist of transformed epithelial 
cells surrounded by a stroma that contains numerous cell types. Understanding the 
kinetics of stromal activation and characterizing both the cell types involved in the cancer 
stroma as well as their secreted proteins may lead to future therapies to stop breast cancer 
progression. It is unknown how stromal cells communicate with transformed epithelial 
cells to promote tumor growth and metastasis. The transforming growth factor β (TGFβ) 
pathway promotes epithelial to mesenchymal transition (EMT). Our lab has identified a 
secreted protein, aortic carboxypeptidase-like protein (ACLP) that is expressed in the 
breast cancer stroma and can exert effects by activating the TGFβ pathway. The role of 
ACLP in EMT during cancer progression is not known. We hypothesize that changes in 
the breast cancer stroma drive cancer progression and correlate with increased expression 
of α-smooth muscle actin (α-SMA) and collagen I (Col I) in stromal fibroblasts and that 
ACLP promotes EMT in the cancerous mammary epithelium. The first goal of this 
project was to develop an in vivo mouse model to first track and then isolate activated 
cells in the breast cancer stroma. The second goal was to test whether ACLP induces 
gene expression changes consistent with EMT. To identify changes in the breast cancer 
stroma we crossed mice expressing the Her2/neu receptor, which is part of the epidermal 
growth factor receptor family and occurs in 20-30% of all human breast cancers, with 
transgenic mice harboring α-SMA (SMA-mCherry) and collagen (Col I-Tpz) promoters 
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driving red and green variants of green fluorescent protein (GFP) respectively. Initial 
experiments characterized the expression of these reporters at baseline and in tumors. 
Both the tumor and mammary gland tissue were isolated and a new method to detect 
fluorescent reporter activity was developed. Whole mount and sections of the tumors and 
the surrounding stroma defined at least two distinct cell populations: those that express 
SMA and those that express Col I, and a possibility of a third population expressing both. 
In contrast to the stroma of a normal mammary duct, which contained dispersed Col I+ 
cells and not cells of the other two populations, the stroma in the tumor sections 
contained a population of SMA+ cells and an increase in Col I+ cells dispersed on the 
periphery of the tumor. Aligned streaks of Col I+ cells were identified. Normal murine 
mammary gland (NMuMG) cells treated with ACLP showed a decrease in E-cadherin 
mRNA levels and increase in vimentin mRNA levels. Immunofluorescence staining 
revealed decreased E-cadherin on the cell borders after ACLP treatment, and, when also 
treated with TGFβ results in increased detected intracellular vimentin. In summary, we 
developed a new model to detect changes in the stroma associated with breast cancer 
development as well as a procedure for preserving fluorescence in mouse tissue for 
analysis. We also found evidence to support the idea that ACLP promotes EMT. Ongoing 
work will characterize the stromal cells by flow cytometry and expression profiling and 
develop strategies to target stroma-derived proteins to treat breast cancer.  
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INTRODUCTION 
Breast Cancer Heterogeneity and Therapies 
Breast cancer is the second most common type of cancer globally and the most 
common among women. Its incidence is greatest in North America, and in 2012 in the 
United States alone 41,555 men and women died from breast cancer 
(http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp, accessed March 13, 2016; 
Breast Cancer Statistics, 2015). Most breast cancers are classified as carcinomas because 
tumor cells arise from the epithelial lining of the mammary tissue (Hong, 2010).  
Breast cancer is heterogeneous and subtypes exist with respect to certain 
pathological markers including estrogen receptors (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER2) (Prat & Perou, 2011). Different types 
of breast cancers will be “positive” for any combination of these receptors, or may be 
negative for all three (so called “triple-negative”) (Prat & Perou, 2011). Luminal A and 
Luminal B subtypes tend to express hormone receptors. HER2-enriched subtypes tend to 
have overexpression of HER2. Basal-like and claudin-low subtypes are usually triple-
negative. Normal-like breast cancers do not predominantly express one receptor type 
(Skibinski & Kuperwasser, 2015).  
Therapies for breast cancer include surgery, chemotherapy, and targeted therapy. 
Surgery involves removal of the primary tumor and surrounding lymphatics (Akram & 
Siddiqui, 2012). Current chemotherapies are administered either individually or in 
combination and include anthracyclines such as doxorubicin and taxanes such as 
paclitaxel (Akram & Siddiqui, 2012). Specific targeted therapies are prescribed either 
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based on pathological markers expressed in the particular type of breast cancer or for the 
purpose of disrupting processes necessary for tumor development. Hormone receptor-
positive breast cancers (ER or PR positive) are treated with drugs that inhibit activation 
of ER. Tamoxifen, initially a prodrug, is metabolized and converted into a competitive 
inhibitor for estrogen. Aromatase inhibitors repress peripheral estrogen synthesis. HER2-
enriched breast cancer is treated using targets for HER2, such as the antibody 
Trastuzumab. More general cancer therapies target processes such as angiogenesis. For 
example, the antibody Bevacizumab targets vascular endothelial growth factor (VEGF) to 
prevent angiogenesis (Akram & Siddiqui, 2012).  
 
Metastasis and the Epithelial to Mesenchymal Transition (EMT) 
One capability that most cancers share is the ability to invade other tissues and 
metastasize (Hanahan & Weinberg, 2000). Metastasis first begins with invasion of the 
cancer cells into the immediate surroundings. Next, the cells enter the vasculature via a 
process called intravasation. The cells then undergo extravasation into distant locations 
and form new cancerous lesions that will eventually grow and continue to spread. When 
cancer cells metastasize, they develop a set of traits that enable them to invade the 
surrounding tissue. Cells will lose polarity and attachments to neighboring cells, become 
more motile, increase expression and secretion of matrix-degrading enzymes, and 
develop resistance to apoptosis during a transformative program called the epithelial-to-
mesenchymal transition (EMT) (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 
2011). 
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Loss of polarity and epithelial cell-cell junctions is a hallmark of EMT (Hanahan 
& Weinberg 2011). Tight junctions formed by the proteins claudin and occludin, as well 
as junctions formed by desmosomes and connexins, are dissolved while their respective 
proteins are downregulated. Importantly, a “cadherin switch” occurs consisting of a 
coordinated degradation and decrease in expression of E-cadherin with an increased 
expression of N-cadherin. As a result, cells lose the affinity for binding to neighboring 
cells and instead interact weakly with mesenchymal cells to promote migration into the 
surrounding tissue. Furthermore, expression of neural cell adhesion molecule (NCAM) 
facilitates the formation of focal adhesions (Lamouille et. al., 2014). During EMT the 
actin cytoskeleton of cells is reorganized to allow for contraction and motility. 
Additionally, matrix metalloproteases (MMP) are released which degrade extracellular 
matrix components and allow for invasion of these newly motile transformed cells. 
Additional changes in epithelial and mesenchymal markers are apparent in intermediate 
filaments, namely a decreased expression of the epithelial marker, cytokeratin, and an 
increase in expression of the mesenchymal marker, vimentin (Lamouille et. al., 2014).  
 
Transforming Growth Factor β Signaling in Epithelial to Mesenchymal Transition 
Several transcription factors are known to drive the epithelial-to-mesenchymal 
transition by repressing epithelial genes and activating mesenchymal genes including 
SNAIL, TWIST, and ZEB (Lamouille et. al., 2014). These transcription factors are 
regulated by transforming growth factor β (TGFβ) signaling and phosphorylation of a 
group of transcription factors known as SMADs. SMAD signaling results in upregulation 
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of SNAIL, TWIST, and ZEB, as well as direct activation of some mesenchymal genes, 
such as fibronectin, vimentin, and collagen α1 (Lamouille et. al., 2014). TGFβ signaling 
feeds into the canonical WNT signaling pathway by disrupting E-cadherin expression at 
the cell membrane, causing it to release β-catenin and increase its cytoplasmic levels. The 
canonical WNT signaling pathway also promotes EMT in a mechanism that involves 
both E-cadherin, and the second messenger β-catenin. In the epithelial phenotype E-
cadherin is expressed in the cell membrane and its intracellular domain binds β-catenin. 
During EMT WNT binds to the frizzled receptor, leading to the inhibition of GSK3β. 
GSK3β normally leads to degradation of both β-catenin and SNAIL, so when GSK3β is 
inhibited, both β-catenin and SNAIL accumulate in the cytoplasm and can drive the 
switch to a mesenchymal phenotype (Lamouille et. al., 2014).  
Other signals that promote EMT include hypoxia of growing tumors, resulting in 
activation of the transcription factor HIFα which upregulates TWIST, and inflammatory 
cytokines such as interleukin-6 (IL-6), which not only leads to upregulation of SNAIL 
and TWIST but also correlates with the cadherin switch and upregulation of vimentin 
(Lamouille et. al., 2014).  
 
HER2 and Epithelial to Mesenchymal Transition 
Some breast cancers are marked by overexpression of HER2, so called HER2-
enriched breast cancers, which also plays a role in activation of the EMT program 
(Lamouille et. al., 2014). Epidermal Growth Factor (EGF) activates its receptor EGFR3 
to upregulate SNAIL and TWIST and induce endocytosis of E-cadherin. Cancer cells are 
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also able to undergo EMT as a result of stimulation of HER2 by EGF (Cheon & Orsulic, 
2011).  
 
Cancer Stroma  
 Tumors are more than just a cluster of cancerous cells. An important entity in the 
tumor’s growth and development is the stroma, which consists of numerous cell types 
and extracellular matrix (ECM) components (Hanahan & Weinberg, 2000). New blood 
vessels form from old ones as a result of vascular endothelial growth factor (VEGF) 
signaling during tumor development in a process called angiogenesis. Smaller vessels are 
lined with endothelial cells and surrounded by pericytes, while larger vessels contain a 
thick smooth muscle layer. The tumor microenvironment, or the stroma surrounding the 
tumor, resembles a pro-inflammatory state, and so contains immune cells that contribute 
numerous secreted products to the environment such as chemokines and cytokines 
(Hanahan & Weinberg, 2011).  
Cancer Associated Fibroblasts (CAF) have numerous functions in the cancer 
stroma, including angiogenesis and ECM deposition and remodeling, which contributes 
to advancing tumor development (Hanahan & Weinberg, 2000). CAFs consist of multiple 
distinct subpopulations. The existence of different populations could be a result of 
differentiation from various cell types, or even due to differences in activation states. 
CAFs have been characterized by the expression of various markers. One well-described 
CAF marker is α-SMA, which is also found in smooth muscle cells, myoepithelial (ME) 
cells, pericytes, and myofibroblasts (Marsh et. al., 2013). Cells that express α-SMA are 
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capable of contraction, and some are even capable of motility. Type I collagen (Col I) is 
another marker of cells that secrete extracellular matrix components such as CAFs 
(Marsh et. al., 2013). Overexpression of collagen leads to fibrosis, and in the case of 
tumor development, leads to what is known as a desmoplastic reaction. This will often 
appear as an accumulation of fibrotic stroma surrounding and restricting the tumor. In 
some instances fibrotic cores will arise within the tumor. Other CAF markers include 
vimentin, fibroblast activation protein (FAP), fibroblast-specific protein 1 (FSP1; also 
known as S100A4), and platelet derived growth factor receptor β (PDGFRβ) (Sugimoto 
et. al., 2006). It is thought that the cancer stroma confers resistance to targeted therapies. 
For example, buildup of fibrotic tissue surrounding the tumor may physically prevent 
therapies from reaching the tumor (Balkwill et. al., 2012). Furthermore, it was found that 
stromal fibroblast secreted factors can protect the tumor from certain therapies. 
Therefore, further investigating the cancer stroma could result in identifying novel targets 
to eliminate stroma-induced resistance to therapy (Straussman et. al., 2012). 
 
Aortic Carboxypeptidase Like Protein (ACLP) 
Aortic Carboxypeptidase Like Protein (ACLP) is a stromal protein encoded by the 
AEBP1 gene and secreted by fibroblasts, myofibroblasts, and vascular smooth muscle 
cells. Human ACLP is 1158 amino acids long and consists of an extensin domain rich in 
lysine and proline, a discoidin-like domain, and an inactive carboxypeptidase domain 
(Layne et. al. 1998). ACLP plays a role in mediating pulmonary fibrosis as well as 
stimulating fibroblast differentiation into myofibroblasts by upregulating α-SMA and 
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collagen. It does this partially through TGFβ signaling. It has been shown that ACLP 
partially exerts its effects by directly binding to TGFβR2, but it can also promote 
collagen expression in an independent manner from the TGFβ pathway (Tumelty et. al., 
2014). 
Correlations have been found between ACLP expression and cancer progression. 
TGFβ has been shown to upregulate a 10 gene set, including AEBP1 and other genes 
involved in collagen remodeling, which correlates with poor survival in ovarian cancer 
(Cheon et. al., 2014). It has also been shown that ACLP causes upregulation of the pro-
inflammatory NF-κβ (Majdalawieh et. al., 2007), which leads to angiogenesis and tumor 
cell proliferation and invasiveness (Hanahan & Weinberg, 2011). Furthermore, ACLP 
has been demonstrated to confer resistance to the inhibition of the melanoma oncogene 
BRAF, again related to the NF-κβ pathway (Hu et. al., 2013). It is not well understood 
what role ACLP has in communication between CAFs and the developing tumor during 
metastasis. 
 
Goals 
First, we aim to develop an in vivo model for observing the stromal reaction over 
time throughout mammary tumor development. To do so we crossed transgenic mice 
with fluorescent reporters attached to the promoters for α-SMA and Col I and with the 
HER2/neu gene driven by the mouse mammary tumor virus (mmtv) promoter to drive 
mammary tumor formation. Our second goal is to identify distinct CAF populations 
based on differences in reporter fluorescence. Subsequently we aim to isolate CAFs using 
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cell sorting to characterize their expression profile. Finally, we are investigating the role 
ACLP has in signaling between CAFs and tumor cells. We hypothesize that stromal 
activation surrounding the cancerous mammary epithelium will occur and consist of an 
increase in populations of cells expressing the CAF markers α-SMA and Col I, and that 
ACLP plays a role in communication between stromal CAFs and cancer cells. Although 
it is known that myofibroblasts secrete ACLP, which subsequently stimulates 
differentiation of fibroblasts into myofibroblasts, it is unknown what role ACLP has in 
the cancer stroma.  
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METHODS 
In vivo Mouse Model 
Mice harboring both the Col1a1 promoter driving GFP-Topaz and the α-SMA promoter 
driving mCherry were generated from two separate mouse strains expressing Col I-Tpz 
and SMA-mCherry obtained from Dr. David Rowe (Kalajzic et. al., 2008). The double 
transgenic mice were again crossed with mice harboring the mmtv promoter driving 
HER2/neu overexpression that were obtained from Jackson Laboratories. All animal 
experiments were approved by the Boston University Institutional Animal Care and Use 
Committee. 
 
Cell Culture 
Normal Murine Mammary Gland (NMuMG) cells (ATCC) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 10 
μg/mL insulin (Sigma). Plates reached 90% confluency before being passaged with 
0.25% trypsin and plated for experiments. Cells were incubated at 37° C in 5% CO2. 
Cells were treated in 1% FBS DMEM with transforming growth factor β1 (R&D 
Systems) and recombinant aortic carboxypeptidase like protein (rACLP) generated as 
previously described (Tumelty et. al., 2014).  
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Tissue Isolation and Fixation 
Tissue was isolated from SMA-mChry+/Col I-Tpz+ mice and Her2+/SMA-
mChry+/Col I-Tpz+ mice. Isolated tissues for whole mounting were washed in cold 
phosphate buffered saline (PBS; 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L 
KH2PO4, pH 7.4). The gland was laid out flat on a glass slide, covered with a second 
slide, and gently pinched. The slides were stabilized with tape before imaging. Isolated 
tissues for sectioning were fixed in 4% paraformaldehyde (PFA)-PBS (Santa Cruz) in the 
dark overnight before processing, sectioning, and imaging. 
 
Preparation of Frozen sections 
Fixed tissues were soaked in 30% sucrose-PBS in the dark overnight. Tissue was 
embedded in liquid OCT compound (Tissue-Tek) using 15 x 15 x 5 mm base molds 
(Thermo Fisher). OCT-filled molds were frozen with liquid nitrogen and stored at -80°C. 
Tissue sectioning was performed at cryotome (Tissue Tek Cryo 2000). Tissue sections 
were washed with cold PBS before being mounted to preserve fluorescence with 
Diamond Antifade Mountant with DAPI (Thermo Fisher). 
 
Preparation of Paraffin Sections 
Mammary gland tissue fixation and embedding in paraffin was based on a 
protocol from Liss and colleagues (Nakagawa et. al. 2015). In the original method, 
harvested tissue was first processed at 4°C in the dark according to Table 1 and 
embedded in paraffin wax (Leica Biosystems, Paraplast Embedding Media #503002). 
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Subsequently, tissue was sectioned as described below before being fixed overnight as 
described above. This protocol was modified and that the tissue was first fixed overnight 
in PFA-PBS. Fixed tissues were processed at 4°C in the dark according to Table 2. 
Paraffin (Leica Biosystems, Paraplast Embedding Media #503002) baths were made by 
heating and melting at 56°C. Processed tissue was embedded in molten paraffin using 24 
x 24 x 5 mm stainless steel base molds (Ted Pella). Embedded tissue was cooled and 
stored at 4°C. Tissue sectioning was performed with a microtome. Sections were heated 
at 40°C for 30 minutes in the dark before being deparaffinized at 4°C in the dark 
according to Table 3. Tissue sections were mounted with Diamond Antifade Mountant 
with DAPI (Thermo Fisher). 
Table 1. Manual Tissue Processing According to Nakagawa et. al., 2015. 
Tissues were processed at 4°C in the dark. Ethanol and xylenes were used to dehydrate 
the tissue. Tissues were subsequently soaked in molten paraffin (at 56°C) in the dark.  
 
Concentration Solution Time Repetitions 
95% Ethanol Overnight 1 
100% Ethanol 1 hour 4 
100% Xylenes 1 hour 3 
100% Paraffin 1 hour (56°C) 4 
 
Table 2. Manual Tissue Processing Modified from Nakagawa et. al., 2015. 
Tissues were processed at 4°C in the dark. Ethanol and xylenes were used to dehydrate 
the tissue. Tissues were subsequently soaked in molten paraffin (at 56°C) in the dark.  
 
Concentration Solution Time Repetitions 
95% Ethanol 30 min 2 
100% Ethanol 30 min 2 
100% Xylenes 30 min 2 
100% Paraffin 30 min (56°C) 2 
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Table 3. Tissue Deparaffinization for Histology 
Tissue sections were deparaffinized and washed at 4°C in the dark using subsequent 
dunks in xylenes, ethanol, and Tris Buffered Saline (TBS; 20 mM Tris and 150 mM NaCl 
in water adjusted to pH 7.6) .  
Concentration Solution # of Dunks Repetitions 
100% Xylenes 20 2 
100% Ethanol 5 2 
1x TBS 20 1 
 
Reverse Transcription Polymerase Chain Reaction and Quantitative Real Time 
Polymerase Chain Reaction 
 RNA was isolated from NMuMG cells using the GeneJET RNA Purification Kit 
(Thermo Fisher Scientific) following treatment. Extracted RNA concentration was 
measured using the Take3 Microvolume Plate (BioTek) and Gen5 Data Analysis 
Software (BioTek). The Maxima First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific) was used to make cDNA. Luminaris Color HiGreen High ROX Master Mix 
and 40x Yellow Sample Buffer (Thermo Fisher Scientific) was used to amplify cDNA. 
Primer sequences (Table 4) were determined using PrimerBank. Amplification was run 
using 7300 Real Time PCR System software (Applied Biosystems). The ΔΔCt method 
was used to analyze amplification data. 
Table 4. Primers for Quantitative Real-Time PCR. 
Gene  Forward Primer 5’3’ Reverse Primer 5’3’ 
E-cadherin GACGCTGAGCATGTGAAGAA CAGGACCAGGAGAAGAGTGC 
GAPDH AGGTCGGTGTGACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Vimentin CGGCTGCGAGAGAAATTGC CCACTTTCCGTTCAAGGTCAAG 
 
Immunofluorescent Staining  
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 NMuMG cells were plated on poly-lysine (10 μg/mL poly-L-lysine hydrobromide 
(Sigma Aldrich), 0.15 M boric acid, pH 8.5) coated chamber slides and incubated 24 
hours before treatment. After treatment cells were fixed in 4% PFA in PBS (Santa Cruz), 
permeablized with PBST, and blocked with 3% bovine serum albumin (BSA)-PBST. 
Cells were incubated with primary antibody (Table 5) in 3% BSA-PBST followed by 
secondary antibody (Table 5) in 3% BSA-PBST in the dark. Slides were mounted with 
Diamond Antifade Mountant with DAPI (Thermo Fisher).  
 
Table 5. Antibodies for Immunofluorescence 
Antibodies used for immunofluorescent staining of NMuMG cells. 
Primary Ab Animal Concentration ID# 
Anti-E-cadherin Mouse 1:500 BD Biosciences 610181 
Anti-IgG Mouse 1:250 Santa Cruz SC-2025 
Anti-Vimentin Mouse 1:250 BD Biosciences 550513 
Secondary Ab Animal Concentration ID# 
Alexa Fluor 568 
Anti-Mouse IgG 
Donkey 1:200 Thermo Fisher A10037 
 
Image Analysis 
Imaging was performed with the Nikon Eclipse TE2000-E microscope, the Nikon DS-
Qi1Mc camera, and NIS Elements BR software. Fluorescent images were merged using 
ImageJ software. 
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RESULTS 
 Epithelial-derived cancers such as breast cancer consist of transformed epithelial 
cells surrounded by a stroma that contains numerous cell types. The function and 
composition of the tumor stroma is largely unknown. The timing of stromal activation 
during tumor development and which fibroblast populations arise throughout the process 
are also unknown. The first goal was to develop an in vivo mouse model to define the 
kinetics of activation of fibroblasts in the cancer stroma and isolate different CAF 
populations found in the stroma by their expression of α-SMA or Col I. An additional 
goal was to better understand the role of the stromal derived protein ACLP in breast 
cancer. We hypothesize that there will be increased expression of α-SMA or Col I in 
stromal cells in conjunction with development of Her2+ breast cancer and that we will 
find three populations: those expressing α-SMA, those expressing Col I, and those 
expressing both. We also hypothesize that that ACLP secreted by the stroma is involved 
in promoting EMT in cancer cells during tumor development. 
 
MOUSE MODEL CHARACTERIZATION 
 
Whole Mount Imaging of Mammary Gland Isolated from In Vivo Model Shows Baseline 
Architecture of α-SMA+ and Col I+ Populations 
We first attempted to characterize expression of α-SMA and Col I at baseline in 
non-cancerous mammary tissue. To identify the cell types that express SMA and collagen 
in the normal mammary gland, tissue was isolated from transgenic mice, washed in cold 
PBS, and gently pinched between two glass slides for whole mount imaging using a 
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fluorescence microscope. Duct structures (Figure 1A, arrow), including the terminal end 
bud (Figure 1B) composed of α-SMA expressing cells, which represents the 
myoepithelial cell layer of the mammary duct. Dispersed cells expressing Col I were 
detected in close proximity to and surrounding the duct. Adipose tissue was observed 
(Figure 1B), as much of the mouse mammary gland is made of fat cells (Gartner & Hiatt, 
2014). Developed duct structures from an older mouse exhibited lobular units branching 
off the ducts that contained α-SMA and Col I-expressing cells (Figure 1C,D). We 
conclude that at baseline the mammary duct structures are clearly defined by their 
myoepithelial cell layer composed of α-SMA expressing cells. Surrounding the duct 
structures at baseline is a diffuse population of Col I expressing cells. As expected, blood 
vessels in the tissue surrounding ducts expressed α-SMA (Figure 1A).  
 
Frozen Sectioning of Fluorescent Mammary Gland Tissue Did Not Preserve Tissue 
Morphology 
It is known that fluorescent proteins, when not handled carefully, can be 
inactivated (Nakagawa et. al. 2015). In order to preserve fluorescence, tissue containing 
fluorescent reporters must usually be kept cold and dark. One method of sectioning tissue 
that preserves fluorescence is frozen sectioning (Jockusch et. al., 2003). Our goal was to 
optimize methods to section the tissue in order to add additional markers in the future to 
better characterize the stroma. We first tested the frozen sectioning method to determine 
whether the GFP fluorescence and mammary gland morphology were preserved. 
Fluorescence was preserved, as seen by the α-SMA+ vessel structure on the right and the  
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Figure 1. WHOLE MOUNT MAMMARY GLAND FLUORESCENT IMAGING. 
Tissue was isolated from mice harboring the promoters for α-smooth muscle actin driving 
mCherry and collagen driving GFP-Topaz. Tissue was directly pinched between two 
glass slides and stabilized with tape. A-B) Ten week old mouse mammary gland. C-D) 
Thirty six week old mouse mammary gland, possessing lobular units. 
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oblique section of an α-SMA+ duct structure on the left (Figure 2). However, two 
problems were apparent. The tissue was fragmented and significant autofluorescence was 
observed (Figure 2). Although this method preserves fluorescence, the morphology was 
not adequately preserved and significant autofluorescence hindered further analysis.  
 
Optimized Paraffin Processing and Sectioning Method Preserves Tissue Fluorescence 
and Morphology while Minimizing Autofluorescence 
While paraffin sections generally have better tissue morphology than frozen 
sections, this method does not generally preserve fluorescence and additionally results in 
autofluorescence (Swenson et. al., 2007). Recently, a new method was developed by 
others that took advantage of the benefits of paraffin embedding and also preserves 
fluorescence (Nakagawa et. al. 2015). To determine if this method was suitable for the 
fluorescent reporters in the transgenic mice, this method, consisting of processing, 
sectioning, and fixing sections in 4% PFA-PBS (Table 1), was performed on tissue from 
mice harboring the α-SMA-mCherry and Col I-Tpz transgenes. First, aorta was used 
because we know that the vessel wall contains a vascular smooth muscle layer that 
expresses α-SMA and an adventitia layer that expresses Col I. Although fluorescence was 
preserved, several problems were encountered. The tissue was shriveled and sections 
exhibited strong autofluorescence. Using this method as a starting point, our goal was to 
optimize this method for our studies. We rearranged the steps such that the tissue was 
fixed first and then processed with significantly shorter steps (Table 2), prior to 
sectioning. In  
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Figure 2. AUTOFLUORESCENCE AND TISSUE FRAGMENTS DETECTED IN 
FROZEN SECTIONS OF FLUORESCENT TISSUE. Tissue was isolated from mice 
harboring the promoters for α-smooth muscle actin driving mCherry and collagen driving 
Tpz. Tissue was fixed in paraformaldehyde, soaked in sucrose, embedded in OCT, and 
sectioned using a cryotome. Tissue sections were stained with DAPI for nuclear 
visualization and mounted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMA-mCherry Col I-Tpz Merge + DAPI 
Vessel Duct 
Autofluorescence Fragment 
 19 
the optimized method, harvested tissues were first fixed overnight. Fixed tissues were 
processed at 4°C in the dark according to Table 2 and finally embedded in paraffin. 
Embedded tissue was cooled and stored at 4°C prior to tissue sectioning. To prepare 
sections for imaging they were heated at 40°C for 30 minutes in the dark before being 
deparaffinized at 4°C in the dark according to Table 3. Tissue sections were mounted 
with Diamond Antifade Mountant with DAPI. A cross section of an aorta using this 
method is presented in Figure 3A. The vessel wall includes a thick layer of α-SMA+ 
cells, which are vascular smooth muscle cells. Surrounding this layer is a Col I+ layer of 
adventitial fibroblasts. Within the smooth muscle layer dimly autofluorescent bands of 
elastin were observed. This autofluorescence was significantly less observed in the aorta 
sections processed by the original method described by Liss and colleagues (Nakagawa 
et. al. 2015) (compare Figure 3A with Figure 3B). These studies determined that by 
both performing initial fixation in 4% PFA followed by rapid manual processing that 
both tissue morphology is preserved and reporter fluorescence is maintained. 
 
Analysis of Mammary Structures and Stroma at Baseline Using Optimized Paraffin 
Processing and Sectioning Method 
We next wanted to examine the expression of these stromal reporters in normal 
mouse mammary tissue. The structure in Figure 4A is evidently a blood vessel 
comprised of detectable α-SMA+ vascular smooth muscle cells because along the vessel 
structure are transverse striations, which are characteristic of blood vessels seen in other 
tissue samples in our in vivo model. Surrounding the vessel is a thin adventitial layer  
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Figure 3. METHOD COMPARISON OF TISSUE EMBEDDING AND 
PROCCESSING. Tissue was isolated from mice harboring the promoters for α-smooth 
muscle actin driving mCherry and collagen driving Tpz. Tissue sections were stained 
with DAPI for nuclear visualization and mounted. A) Tissue was fixed in 
paraformaldehyde, dehydrated in ethanol and xylenes, embedded in paraffin wax, and 
sectioned using a microtome. B) Tissue was dehydrated in ethanol and xylenes, 
embedded in paraffin wax, and fixed in paraformaldehyde.  
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Figure 4. BASELINE EXPRESSION OF α-SMA and Col I IN MAMMARY 
TISSUE STROMA. Tissue was isolated from mice harboring the promoters for α-
smooth muscle actin driving mCherry and collagen driving Tpz. Tissue was fixed in 
paraformaldehyde, dehydrated in ethanol and xylenes, embedded in paraffin, and 
sectioned using a microtome. Tissue sections were stained with DAPI for nuclear 
visualization and mounted. A) Blood vessel. B) Mammary duct. 
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consisting of fibroblasts expressing Col I. Nuclei of cells were stained with DAPI, and as 
a result the flattened nuclei of the inner endothelial layer was observed. The α-SMA+ 
structure in Figure 4B was composed of myoepithelial cells and consistent with our 
whole mount findings. These were established to be duct structures due to their absence 
of transverse striations and prominent inner epithelial layer have rounded DAPI-stained 
nuclei rather than flattened ones. Surrounding the duct structure was a small and diffuse 
population of Col I+ cells, similar to what was observed in the whole mount mammary 
gland (compare Figure 1 with Figure 4). We conclude that the baseline architecture and 
expression of Col I and α-SMA in cells is similar to that which was seen in the whole 
mount mammary tissue.  
 
Stromal Activation in Mammary Tumor from Her2+Mouse  
Our long-term goal is to identify changes in the mammary gland stroma in breast 
cancer. Once we were able to characterize the baseline expression Col I and α-SMA in 
the normal mammary stroma at baseline we next wanted to examine the stroma in Her2+ 
mammary tumors and distal tissue. The mCherry and Tpz transgenic mice were crossed 
with HER2-overexpressing mice to drive mammary tumor formation. We hypothesized 
that stromal activation will occur, characterized by an increased expression of α-SMA 
and Col I in the stroma. First, in collaboration with Ana de la Cueva, we investigated 
whether stromal activation was detected in mammary tissue distal to a developing tumor. 
While our ultimate goal is to characterize the kinetics of stromal activation, an initial 
tumor was studied in a 36-week old mouse, when the tumor was easily palpable. The 
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tumor and distal mammary tissue from the same gland were dissected. We first examined 
the tissue distal from the tumor and a duct structure contained inner layer of cells with 
rounded DAPI-stained nuclei surrounded by an α-SMA+ myoepithelial cells (Figure 5). 
Surrounding the duct were several Col I+ cells. These surrounding stromal cells also 
showed low expression of α-SMA. We conclude that although the duct structure appeared 
normal, the expression pattern was consistent with mild stromal activation. Next, we 
looked at the stroma of a tumor driven by Her2 overexpression (Figure 6A). The tumor 
was located in the upper right, represented by a dense collection of DAPI-stained nuclei 
with low expression of α-SMA or Col I (Figure 10A). Along the periphery of the tumor 
streaks of α-SMA or Col I cells were detected. This architecture and expression signature 
is markedly different from what was observed at baseline or even in distal mammary 
tissue (Figure 4 and Figure 5 respectively). The tumor itself exhibited minimal 
expression of α-SMA or Col I (Figure 6). However, immediately surrounding the tumor 
was a dense band of cells with active fluorescent reporters. The cells were primarily 
expressing Col I, but the band also contained sporadic α-SMA+ cells. We conclude that α-
SMA or Col I expression increased in the stroma immediately surrounding the tumor. 
Ongoing work is examining additional tumors at different time points. 
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Figure 5. LOW LEVEL OF STROMAL ACTIVATION IN MAMMARY TISSUE 
DISTAL TO TUMOR. Tissue was isolated from 36 week old mice harboring the Her2 
gene and the promoters for α-smooth muscle actin driving mCherry and collagen driving 
Tpz. Tissue was fixed in paraformaldehyde, dehydrated in ethanol and xylenes, 
embedded in paraffin wax, and sectioned using a microtome. Tissue sections were stained 
with DAPI for nuclear visualization and mounted.  
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Figure 6. IDENTIFICATION 
OF ACTIVATED STROMAL 
CELLS IN BREAST CANCER 
Tissue was isolated from 36 week 
old mice harboring the Her2 gene 
and the promoters for α-smooth 
muscle actin driving mCherry and 
collagen driving Tpz.  
Tissue sections were stained with 
DAPI for nuclear visualization  
and mounted.  
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ACLP AND EPITHELIAL CHANGES 
Transforming Growth Factor β Induces Epithelial to Mesenchymal Transition in Normal 
Murine Mammary Gland Cells 
 It is known that TGFβ induces EMT in mammary gland epithelial cells (Kalluri & 
Weinberg, 2009). Preliminary studies in our laboratory have determined that ACLP can 
promote an EMT phenotype. These studies were repeated using the well-established 
normal murine mammary gland (NMuMG) cell line to assess EMT pathways for 
examining the function of ACLP. Initial experiments were performed to establish the 
methods and markers of EMT using TGFβ treatment. NMuMG cells were treated with or 
without 1 nM TGFβ for 48 hours and RNA was analyzed by qRT-PCR for the epithelial 
marker E-cadherin and the mesenchymal marker, vimentin. All values were normalized 
relative to GAPDH as described in the Materials and Methods. Treatment of NMuMG 
cells with TGFβ decreased E-cadherin levels to less than 20% of the control (Figure 7). 
TGFβ significantly (p<0.05) increased vimentin levels to over 160% of the control. We 
conclude that NMuMG cells treated with TGFβ readily undergo EMT and will be a 
useful cell system to study ACLP function (below). 
 
Aortic Carboxypeptidase Like Protein Induces Epithelial-Mesenchymal Transition in 
Normal Murine Mammary Gland Cells 
 Preliminary work from our laboratory determined that ACLP promotes EMT in 
NMuMG cells (Jager, 2012). We hypothesized that ACLP induces EMT by itself and that 
in conjunction with TGFβ it will induce a greater EMT effect. Compared to the control,  
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Figure 7. TGFβ DECREASES E-CADHERIN AND INCREASES VIMENTIN 
mRNA LEVELS IN NMuMG CELLS. NMuMG cells were treated with 1 nM TGFβ1 
for 48 hours. RNA was extracted at 48 hours. mRNA quantitation was performed as 
described in methods. Representative of three experiments. 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
200
R
el
at
iv
e 
m
R
N
A
/G
A
P
D
H
Control Control TGFβ TGFβ 
E-cadherin Vimentin 
 28 
cells treated with 1 nM TGFβ decreased E-cadherin levels by about 90%, cells treated 
with very low (10 pM) TGFβ decreased E-cadherin levels only by about 60%, treatment 
with ACLP decreased E-cadherin levels by about 70%, and treatment with 10 pM TGFβ 
and ACLP together decreased E-cadherin levels by 85% of the control (Figure 8). We 
conclude that treatment with ACLP decreases mRNA levels of the epithelial marker E-
cadherin, but there is no significant difference between the combination treatment with 
both ACLP and TGFβ compared to treating with either ACLP or TGFβ alone.  
 
Aortic Carboxypeptidase Like Protein Induces Changes in E-cadherin and Vimentin 
Expression in Normal Murine Mammary Gland Cells 
We next wanted to examine the morphology of epithelial cells treated with ACLP 
using immunofluorescence staining. It is known that during EMT E-cadherin is 
downregulated and degraded, while vimentin levels increase. E-cadherin (stained red) 
before being treated appears to be present surrounding each cell on the border between 
cells (Figure 9A). The ACLP-treated cells exhibited E-cadherin expression in a pattern 
consistent with its association with cell-cell contacts, but gaps were also observed 
between cells (Figure 9B). After treatment with TGFβ the E-cadherin signal was less 
prominent on the cell margin (Figure 9C). Gaps were also seen between cells, indicative 
of loss of cell-cell junctions. Treating cells with both ACLP and TGFβ resulted in 
reduced E-cadherin on the cell membrane compared with the controls, and E-cadherin 
was also detected intracellularly (Figure 9D). Low vimentin was detected in the control 
well (Figure 9E). A similar pattern of vimentin expression was detected in ACLP-treated  
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Figure 8. ACLP DECREASES E-CADHERIN EXPRESSION IN NMuMG CELLS. 
NMuMG cells were treated with either 1 nM TGFβ1, 10 pM TGFβ1, 3.75 μg/mL ACLP, 
or both ACLP and TGFβ1 for 48 hours. RNA was extracted at 48 hours. E-cadherin 
mRNA levels were measured as described in methods. The A + T condition represents 
cells treated with both 3.75 μg/mL ACLP and 10 pM TGFβ1. Representative of three 
experiments. 
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Figure 9. ACLP ALTERS E-CADHERIN AND VIMENTIN EXPRESSION IN 
NMuMG CELLS. NMuMG cells were treated with either 10 pM TGFβ1, 3.75 μg/mL 
ACLP, or both ACLP and TGFβ1 for 48 hours. Cells were fixed with 4% PFA in PBS 
and stained with antibody for E-cadherin and vimentin. Signal was detected using 
antibody conjugated with Alexa Fluor 568. Cells were stained with DAPI for nuclear 
visualization and mounted. Representative images of two wells. A) Control stained for E-
cadherin. B) Treated with 3.75 μg/mL ACLP and stained for E-cadherin. C) Treated with 
10 pM TGFβ1 and stained for E-cadherin. D) Treated with 3.75 μg/mL ACLP and 10 pM 
TGFβ1 and stained for E-cadherin. E) Control stained for vimentin. F) Treated with 3.75 
μg/mL ACLP and stained for vimentin. G) Treated with 10 pM TGFβ1 and stained for 
vimentin. H) Treated with 3.75 μg/mL ACLP and 10 pM TGFβ1 and stained for 
vimentin. 
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cells (Figure 9F). Cells treated with either TGFβ alone (Figure 9G) or with both ACLP 
and TGFβ (Figure 9H) showed an increased amount of vimentin expression. Vimentin 
detection was most intense in the cells treated with both ACLP and TGFβ. We conclude 
that ACLP decreases E-cadherin levels and in conjunction with TGFβ has an even greater 
effect. Under these experimental conditions, ACLP in conjunction with low levels of 
TGFβ altered vimentin expression.  
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DISCUSSION 
In summary, we have gained insight into how expression of α-SMA or Col I 
changes during stromal activation and what role ACLP has in communication between 
the stroma and developing tumor. We developed a histological method that permitted 
visualization of the mammary gland stromal architecture and preserved expression of α-
SMA and Col I fluorescent reporters (Nakagawa et. al. 2015). We also found that along 
the tumor margin there is stromal activation in the form of increased populations of α-
SMA+ or Col I+ cells and reorganization of the stromal architecture, although this stromal 
activation was not found in distal mammary tissue from the same mammary gland in the 
same mouse as the tumor. Finally, we found that ACLP decreases E-cadherin expression 
in mammary epithelial cells. In conjunction with TGFβ, ACLP has an even stronger 
effect on E-cadherin and causes increased expression of vimentin in mammary epithelial 
cells.  
Our project is just one of many efforts to better understand the role of stroma in 
cancer. Several breast cancer xenograft models exist which use luciferase for 
bioluminescent analysis of TGFβ signaling during metastasis (Kang, 2016). One research 
team has developed a humanized mouse model of breast growth, where mouse mammary 
epithelium and fibroblasts have been cleared and instead replaced with their human 
counterpart cells (Proia & Kuperwasser, 2006). Another mouse model, called 
Prorainbow, expresses combinatorial fluorescent proteins which allow for different cell 
types in benign and cancerous prostate to be detected based on varying fluorescence 
(Fang et. al., 2015). One problem we have observed so far in our model relates to 
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identification of cells which express both α-SMA and Col I. Sectioning and imaging 
cancer tissue is limited in that 2-dimensional imaging could result in overlap of one cell 
expressing α-SMA with another cell expressing Col I, thus leading to incorrect detection 
of “double positive” cells. A solution to this problem is sorting these cells by 
fluorescence with flow cytometry. Another question we must answer is: what is the 
threshold intensity to determine which cells are α-SMA+ or Col I+? Cells can express 
varying intensity in a fluorescent reporter, and so one may or may not consider a 
fluorescent stromal cell to be activated. Although the Col I expression is strong in the 
stromal cells of Figure 5, it is unclear whether the mild transcription of α-SMA is 
significant enough to be called activation.  
We have observed stromal activation using our model in the form of changes in 
the populations of cells expressing α-SMA, Col I, or both. We used these two CAF 
markers in our study, but several others have been identified. For example, one group 
identified a distinct population of FSP1-expressing fibroblasts with very little overlap in 
CAF markers, as compared to other fibroblast populations, which express several CAF 
markers (Sugimoto et. al., 2006). This finding reinforces the idea that multiple CAF 
populations exist which may play distinct roles from each other in cancer progression. 
CAF activation of what is known as the desmoplastic response has also been investigated. 
It is unknown what stimulates this response, but there are several theories. One theory is 
that the response is stimulated by the host to protect itself from the tumor (Ueba et. al. 
1994). Alternatively the tumor itself may stimulate the response in a way similar to 
wound healing that promotes cancer progression (Dvorak, 1986; Schäfer & Werner, 
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2008). We may have detected this desmoplastic response in our tumor section 
represented by the thick band of Col I-expressing cells (Figure 6).  
 Finally, we have demonstrated that ACLP lowers E-cadherin levels and, in the 
presence of TGFβ raises vimentin levels. This is consistent with EMT. This mechanism 
may be similar to that of the TGFβ pathway, where E-cadherin is degraded and 
relocalized into intracellular vesicles. Both myofibroblasts, which are known to secrete 
ACLP (Tumelty et. al., 2014), and CAFs share several similarities, such as their 
expression of α-SMA (Kalluri & Zeisberg, 2006; Franco, Shaw, Strand, & Hayward, 
2010). Preliminary data show that CAFs also secrete ACLP. One finding suggests that 
ACLP stimulates macrophages and induces inflammation, leading to breast cancer 
development (Holloway et. al., 2012). Additionally, a 20 gene set that is upregulated 
during breast cancer as compared to all other cancers was identified and includes AEBP1 
(Yao et. al., 2015). Furthermore, a 100 gene set including AEBP1 was correlated with the 
stromal reaction. Other members of this list include many collagen genes such as 
COL1A1 and the gene for α-SMA (ACTA2) (Cheng, Yang, & Anastassiou, 2013). The 
fact that multiple findings point to ACLP as a mediator of cancer progression supports 
the importance of further investigation of its roles in signaling.  
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FUTURE DIRECTIONS 
 While we have found evidence that ACLP is involved in EMT of cancer cells it is 
currently unknown what role ACLP plays in cancer initiation and progression. By 
implementing the optimized sectioning method that preserves both morphology and 
fluorescence to analyze a greater number of tumors and at different time points. This 
tumor model will enable the purification of stromal cell populations in tumors by their 
expression of α-SMA or Col I by flow cytometry. Once we isolate the various stromal 
cell populations we can better understand what genes each population actively expresses. 
Furthermore, once we isolate these CAFs we plan to imitate and analyze stromal 
activation by co-culture with epithelial cells in vitro. Ultimately we hope to understand 
what role CAFs have in tumor development in order to identify a novel mechanism to 
intercept CAF signaling and possibly to prevent the incidence of CAF altogether, thus 
slowing down cancer progression and decreasing malignancy.  
 
  
 36 
REFERENCES 
Akram, M., & Siddiqui, S. A. (2012). Breast cancer management: past, present and 
evolving. Indian journal of cancer, 49(3), 277. 
 
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a 
glance. Journal of cell science, 125(23), 5591-5596. 
 
Breast Cancer Statistics (2015, August 20). Retrieved March 13, 2016, from 
http://www.cdc.gov/cancer/breast/statistics/ 
 
Cheng, W. Y., Yang, T. H. O., & Anastassiou, D. (2013). Biomolecular events in cancer 
revealed by attractor metagenes. Public Library of Science Computational Biology, 9(2), 
e1002920. 
 
Cheon, D. J., & Orsulic, S. (2011). Mouse Models of Cancer. Annual Review of 
Pathology, 6, 95-119.  
 
Cheon, D. J., Tong, Y., Sim, M. S., Dering, J., Berel, D., Cui, X., ... & Karlan, B. Y. 
(2014). A collagen-remodeling gene signature regulated by TGF-β signaling is associated 
with metastasis and poor survival in serous ovarian cancer. Clinical Cancer Research, 
20(3), 711-723. 
 
Dvorak, H. F. (1986). Tumors: wounds that do not heal: similarities between tumor 
stroma generation and wound healing. The New England journal of medicine, 315(26), 
1650-1659. 
 
Fang, X., Gyabaah, K., Nickkholgh, B., Cline, J. M., & Balaji, K. C. (2015). Novel In 
Vivo model for combinatorial fluorescence labeling in mouse prostate. The Prostate, 
75(9), 988-1000. 
 
Gartner, L. P., & Hiatt, J. L. (2014). Color atlas and text of histology. Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins. 
 
GLOBOCAN Cancer Fact Sheets: Breast cancer. Retrieved March 13 2016, from 
http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp  
 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646-674. 
 
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70. 
 
Holloway, R. W., Bogachev, O., Bharadwaj, A. G., McCluskey, G. D., Majdalawieh, A. 
F., Zhang, L., & Ro, H. S. (2012). Stromal adipocyte enhancer-binding protein (AEBP1) 
 37 
promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog 
signaling. Journal of Biological Chemistry, 287(46), 39171-39181. 
 
Hong, W. K. (2010). Holland-Frei Cancer Medicine (8th ed.). People’s Medical 
Publishing House. 
 
Hu, W., Jin, L., Jiang, C. C., Long, G. V., Scolyer, R. A., Wu, Q., ... & Wu, M. (2013). 
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in 
melanoma. Cell death & disease, 4(11), e914. 
 
Jager, M. (2012). The Role of Aortic Carboxypeptidase Like Protein in Epithelial-
Mesenchymal Transition (Master’s Thesis). Retrieved from Boston University Medical 
Center Alumni Medical Library. 
 
Jockusch, H., Voigt, S., & Eberhard, D. (2003). Localization of GFP in frozen sections 
from unfixed mouse tissues: immobilization of a highly soluble marker protein by 
formaldehyde vapor. Journal of Histochemistry & Cytochemistry, 51(3), 401-404. 
 
Kalajzic, Z., Li, H., Wang, L. P., Jiang, X., Lamothe, K., Adams, D. J., ... & Kalajzic, I. 
(2008). Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor 
population. Bone, 43(3), 501-510. 
 
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. 
The Journal of clinical investigation, 119(6), 1420-1428. 
 
Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6(5), 
392-401. 
 
Franco, O. E., Shaw, A. K., Strand, D. W., & Hayward, S. W. (2010, February). Cancer 
associated fibroblasts in cancer pathogenesis. In Seminars in cell & developmental 
biology (Vol. 21, No. 1, pp. 33-39). Academic Press. 
 
Kang, Y. (2016). Imaging TGFβ Signaling in Mouse Models of Cancer Metastasis. 
Methods in Molecular Biology, 1344, 219-232.  
  
Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial–
mesenchymal transition. Nature reviews. Molecular cell biology,15(3), 178. 
 
Layne, M. D., Endege, W. O., Jain, M. K., Yet, S. F., Hsieh, C. M., Chin, M. T., ... & 
Lee, M. E. (1998). Aortic carboxypeptidase-like protein, a novel protein with discoidin 
and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell 
differentiation. Journal of Biological Chemistry, 273(25), 15654-15660. 
 
 38 
Majdalawieh, A., Zhang, L., & Ro, H. S. (2007). Adipocyte enhancer-binding protein-1 
promotes macrophage inflammatory responsiveness by up-regulating NF-κB via IκBα 
negative regulation. Molecular biology of the cell, 18(3), 930-942. 
 
Marsh, T., Pietras, K., & McAllister, S. S. (2013). Fibroblasts as architects of cancer 
pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1832(7), 
1070-1078. 
 
Nakagawa, A., Von Alt, K., Lillemoe, K. D., Fernández-del Castillo, C., Warshaw, A. L., 
& Liss, A. S. (2015). METHOD SUMMARY. BioTechniques,59(3), 153-155. 
 
Prat, A., & Perou, C. M. (2011). Deconstructing the molecular portraits of breast cancer. 
Molecular oncology, 5(1), 5-23. 
 
Proia, D. A., & Kuperwasser, C. (2006). Reconstruction of human mammary tissues in a 
mouse model. Nature Protocols-Electronic Edition, 1(1), 206. 
 
Schäfer, M., & Werner, S. (2008). Cancer as an overhealing wound: an old hypothesis 
revisited. Nature reviews Molecular cell biology, 9(8), 628-638. 
 
Skibinski, A., & Kuperwasser, C. (2015). The origin of breast tumor heterogeneity. 
Oncogene.  
 
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., ... & 
Cooper, Z. A. (2012). Tumour micro-environment elicits innate resistance to RAF 
inhibitors through HGF secretion. Nature, 487(7408), 500-504. 
 
Sugimoto, H., Mundel, T. M., Kieran, M. W., & Kalluri, R. (2006). Identification of 
fibroblast heterogeneity in the tumor microenvironment.Cancer biology & therapy, 5(12), 
1640-1646. 
 
Swenson, E. S., Price, J. G., Brazelton, T., & Krause, D. S. (2007). Limitations of green 
fluorescent protein as a cell lineage marker. Stem Cells, 25(10), 2593-2600. 
 
Tumelty, K. E., Smith, B. D., Nugent, M. A., & Layne, M. D. (2014). Aortic 
carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation 
through transforming growth factor β receptor-dependent and-independent 
pathways. Journal of Biological Chemistry, 289(5), 2526-2536. 
 
Ueba, T., Nosaka, T., Takahashi, J. A., Shibata, F., Florkiewicz, R. Z., Vogelstein, B., ... 
& Hatanaka, M. (1994). Transcriptional regulation of basic fibroblast growth factor gene 
by p53 in human glioblastoma and hepatocellular carcinoma cells. Proceedings of the 
National Academy of Sciences, 91(19), 9009-9013. 
 
 39 
Yao, F., Zhang, C., Du, W., Liu, C., & Xu, Y. (2015). Identification of Gene-Expression 
Signatures and Protein Markers for Breast Cancer Grading and Staging. Public Library of 
Science one, 10(9), e0138213. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
CURRICULUM VITAE 
Carl Ceraolo 
ceraoloc@bu.edu, (914) 309-5560 
6 Stanley Avenue, Hastings-on-Hudson, NY 10706 
Year of Birth: 1992 
Education 
Boston University, School of Medicine               Boston, MA 
    Masters of Science in Medical Science        Anticipated Graduation May 2016 
 
Boston College, College of Arts and Sciences                  Chestnut Hill, MA 
    Bachelor of Science in Biology                           May 2014  
 
Work Experience 
    Boston University School of Medicine Department of Biochemistry                   Boston, MA 
    Teaching Assistant and Tutor          September 2015-Present 
    Biochemistry and Cell Biology (170 students), Human Physiology (170), Medical Pharmacology (75) 
 Planned and conducted weekly review sessions, prepared weekly practice quizzes, answered 
questions to clarify lecture material, organized and conducted individual weekly tutoring sessions 
 
    Laboratory of Matthew Layne, PhD – Boston University School of Medicine           Boston, MA 
    Graduate Student        July 2015-Present 
 Investigated role of aortic carboxypeptidase-like protein in early signaling during tumor 
development and metastasis. Developed in vivo mouse model for identifying cancer-associated 
fibroblasts in mammary gland tumor stroma. 
 
    Citywide Mobile Response                  Bronx, NY 
    Emergency Medical Technician and Motor Vehicle Operator               June-August 2014 
 Assessed patient condition, maintained adequate airway, breathing, and circulation, transported 
patients, drove ambulance 
 
    Boston College Department of Earth & Environmental Sciences                Chestnut Hill, MA 
    Teaching Assistant - Earth Materials (Lecture and Lab)                January-May 2014 
 Supervised two lab sections per week (14 students each), prepared lab demonstrations and 
worksheets, planned and conducted review sessions for exams, answered questions to clarify 
lecture material 
 
    Laboratory of Kenneth Williams, PhD – Boston College                 Chestnut Hill, MA 
    Research Assistant                   September 2012-April 2013 
 Investigated role of CNS macrophages in pathogenesis of lentiviral infection; responsible for IHC 
staining of tissue for SIV infected macrophages, counting cells, and calculating cell density. 
 
    Laboratory of Manikkam Suthanthiran, MD – Weill-Cornell Medical College      New York, NY            
    Research Volunteer                        July-August 2012 
 Lab aimed to find noninvasive alternative to kidney biopsy by mRNA and microRNA analysis to 
detect kidney transplant rejection; isolated RNA from renal transplant patient urine. 
 
    Rogosin Institute- New York Presbyterain Hospital        New York, NY                
    Research Assistant                                  June-August 2011 
 Investigated the correlation between demographic data on renal transplant donors and recipients to 
determine transplant effectiveness; responsible for collecting data from 200 patients. 
 41 
Publications 
    Juluru K, Rotman J, Masi P, Spandorfer R, Ceraolo C, Giambrone A, Serur D, Hartono C.  
    Semiautomated CT-Based Quantification of Donor Kidney Volume Applied to a Predictive Model of  
    Outcomes in Renal Transplantation. American Journal of Roentgenology. 2015;204(5). 
 
 
Leadership Experience 
    Graduate and Professional Leadership Council of Boston University                Boston, MA  
    Executive Board 
 Arranged meetings with Associate Provost for Graduate Affairs to voice concerns about graduate 
affairs on behalf of the graduate and professional student body in order to improve graduate 
education and student life. 
 
    Outdoor Club of Boston College                   Chestnut Hill, MA 
    President 
 Directed club operations and development, promoted outdoor culture on campus, spread 
awareness of the club and increased membership from 500 to 1400, planned 20 trips, taught 
leadership and outdoor skills. 
 
    Geology Club of Boston College                           Chestnut Hill, MA 
    Treasurer 
 Created and submitted semester budget proposals to request funding for geological outings. 
 
Volunteer Experience 
    Boston Medical Center, Pediatrics Department              Boston, MA 
    Asthma Education Volunteer            February 2015-Present 
 Conducted information sessions with pediatric asthma patients and their families, informed 
patients about the disease and how their prescribed medication works.  
 
    Massachusetts General Hospital                    Boston, MA 
    Patient Escort Volunteer                  September 2011-May 2012 
 Escorted patients around the hospital by navigating their way to their desired location, transported 
patients between their means of transportation and the patient room. 
 
    Eagle EMS                      Chestnut Hill, MA 
    EMT                     September 2011-May 2014 
 Assessed patient condition, maintained adequate airway, breathing, and circulation, transported 
patients from Boston College to St. Elizabeth’s Medical Center. 
 
Skills 
 Cell culture (mouse primary cells, epithelial cell line), RNA isolation and qPCR, Western blot, 
Immunofluorescent staining, Tissue sectioning 
 Microsoft Word, Excel, PowerPoint, RedCap 
 Conversant in Spanish 
 
Awards and Certifications 
 Eagle Scout, Boy Scouts of America – August 2008 
 New York State Emergency Medical Technician-Basic – September 2014 
